2024 Update on Postmarketing Nutrivigilance Safety Profile: A Line of Dietary Food Supplements Containing Red Yeast Rice for Dyslipidemia

Banach, M, Katsiki, N, Latkovskis, G, Gaita, D, Escobar, C, Pella, D, Penson, PE ORCID: 0000-0001-6763-1489, Fogacci, F, Reiner, Ž and Cicero, AFG (2024) 2024 Update on Postmarketing Nutrivigilance Safety Profile: A Line of Dietary Food Supplements Containing Red Yeast Rice for Dyslipidemia. Archives of Medical Science. ISSN 1734-1922

Preview

Text 2024 Update on Postmarketing Nutrivigilance Safety Profile A Line of Dietary Food Supplements Containing Red Yeast Rice for Dyslipidemia.pdf - Published Version Available under License Creative Commons Attribution Non-commercial Share Alike. Download (95kB) | Preview

Abstract

Introduction: Considering lack of a European standardized postmarketing food supplement surveillance system, some member states and companies have developed their own approaches to monitoring potential AEs to secure a high level of product safety. This paper updates 2021 results of the use of a nutrivigilance system in monitoring the incidence of spontaneously reported suspected AEs associated with RYR-containing food supplements. Material and methods: We report the data from a product marketed under the trademark Armolipid/Armolipid Plus. Postmarketing information was collected in a voluntary nutrivigilance system established by the manufacturing company (Meda Pharma SpA, a Viatris Company, Monza, Italy). From 1st October 2004-31st December 2023, this system captured cases of suspected AEs spontaneously reported by consumers, healthcare professionals, health authorities, regardless of causality. Results: The total number of case reports received mentioning the RYR-food supplement product line increased to 1186, in which 1904 AEs were reported. The total reporting rate of AEs was estimated to be 0.049% of 3,880,865 exposed consumers. Of the 1186 cases, 28 (0.0007%) included suspected SAEs. After careful investigation, 9 cases (0.0002%) and 12 AEs were assessed by the manufacturer as serious and potentially related to exposure to the above-mentioned RYR-based nutraceutical. Off-label reports linked to the newly introduced limitation at 70 years of age were observed, in contrast to the previous analysis. Conclusions: These updated results confirm a very low incidence of RYR suspected AEs. Consumer safety of food supplements could be generally improved by raising awareness of the importance of following the indications and warnings detailed in a food supplement’s labelling.

Item Type:	Article
Uncontrolled Keywords:	1103 Clinical Sciences; General & Internal Medicine
Subjects:	T Technology > TX Home economics > TX341 Nutrition. Foods and food supply Q Science > QH Natural history > QH301 Biology
Divisions:	Pharmacy and Biomolecular Sciences
Publisher:	Termedia Publishing
Date of acceptance:	16 June 2024
Date of first compliant Open Access:	10 February 2025
Date Deposited:	09 Sep 2024 11:55
Last Modified:	04 Jul 2025 09:15
DOI or ID number:	10.5114/aoms/190111
URI:	https://researchonline.ljmu.ac.uk/id/eprint/24095

View Item